Medical Crossfire™: Navigating the Expanding Arsenal of Endocrine Therapies for HR+/HER2– Metastatic Breast Cancer – How Can PROTAC ER Degradation Shift the Standard?

Thanks for your interest in this podcast. Please read this important program information before listening.

Episode Description

In this podcast, experts William J. Gradishar, MD, FASCO, FACP; Stephanie L. Graff, MD, FACP, FASCO; and Cynthia X. Ma, MD, PhD; discuss current and emerging therapeutic options, including next-generation endocrine therapies, to target the estrogen receptor signaling pathway for the treatment of hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (MBC).

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Summarize key characteristics of ESR1 mutations in HR+/HER2– metastatic breast cancer (MBC), including incidence, timing, and impact on treatment efficacy
• Discuss novel therapeutic strategies for targeting the estrogen receptor signaling pathway that have driven the development of next-generation endocrine therapies
• Evaluate safety and efficacy data from recent clinical trials of emerging next-generation endocrine therapies
• Apply new evidence and guideline recommendations to make individualized treatment plans for patients with HR+/HER2– MBC

Acknowledgment of Educational Grant Support

This activity is supported by educational grants from Arvinas and Pfizer, Inc.

Chair:

William J. Gradishar, MD, FASCO, FACP

Betsy Bramsen Professor of Breast Oncology and Professor of Medicine
Chief, Division of Hematology/Oncology
Feinberg School of Medicine
Northwestern University
Chicago, IL

Disclosures: Co-Investigator: Gilead, Menarini Group, Pfizer; Data Monitoring Committee: Lilly, Menarini Group

Faculty:

Stephanie L. Graff, MD, FACP, FASCO

Associate Professor of Medicine
Warren Alpert Medical School
Brown University
Director of Breast Oncology
Brown Health Cancer Institute
Providence, RI

Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: ASCO Advantage, AstraZeneca, Daiichi Sankyo, Genentech, Gilead Sciences, Lilly/Loxo@Lilly, Menarini Stemline, Novartis, Pfizer, Seagen; Grant/Research Funding (Paid to Institution): AstraZeneca, Daiichi Sankyo, Hoffmann-La Roche/Genentech, Lilly, Menarini (Stemline) Group, Novartis; Executive Role: Dempsey Center for Quality Care, Board of Directors (Unpaid Volunteer); Ownership Interests: HCA Healthcare

Cynthia X. Ma, MD, PhD

Professor of Medicine
Clinical Director, Breast Cancer Program
Division of Oncology
Washington University School of Medicine
St Louis, MO

Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AstraZeneca, Bayer, Biovica, Delphi Diagnostics, Eli Lilly, FoRx Therapeutics (ER pos breast cancer treatment landscape), Novartis, Stemline, Tempus; Grant/Research Funding: Pfizer

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER^® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

The staff of Physicians’ Education Resource^®, LLC, have no relevant financial relationships with ineligible companies.

This podcast, including the narration, was developed by PER^® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.

To learn more about this topic, including information on mechanisms of action and clinical trial data for SERDs and PROTACs, go to https://www.gotoper.com/sabcs25protac-enduring.

Release Date

January 23, 2026

Expiration Date

January 23, 2027

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.